Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Files An 8-K Costs Associated with Exit or Disposal Activities

Item 2.05

On May 22, 2017, Ekso Bionics Holdings, Inc. (the Company)
implemented a plan to streamline its operations and reduce its
workforce by approximately 25% in order to lower operating
expenses and reduce cash burn.

The Company is offering severance benefits to the affected
employees, including cash severance payments, grants of
restricted stock units, outplacement services and payment of
health care insurance premiums for specified periods. Each
affected employees eligibility for the severance benefits is
contingent upon such employees execution of a separation
agreement, which includes a general release of claims against the
Company.

The Company expects to record restructuring-related expenses in
2017 of approximately $1.0 million related to termination benefit
costs and other costs associated with the workforce reduction.
Approximately $0.8 million of these expenses are expected to
represent cash expenditures, most of which will be expensed and
paid in the second quarter of 2017, with the remaining cash
expenditures paid in the third quarter of 2017. The remaining
approximately $0.2 million are one-time, non-cash, stock-based
compensation expenses and are expected to be expensed in the
third quarter of 2017.

The charge that the Company expects to incur in connection with
these actions is subject to a number of assumptions, and actual
results may differ. The Company may also incur other charges not
currently contemplated due to events that may occur as a result
of, or associated with, the plan. The Company expects to complete
these actions by the end of the third quarter of 2017.

Forward-Looking Statements

Any statements contained in this Current Report on Form 8-K that
do not describe historical facts may constitute forward-looking
statements. Forward-looking statements may include, without
limitation, statements regarding (i) the timing and amount of
expenditures related to the workforce reduction and anticipated
costs savings, (ii) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(iii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iv) the Company’s future financial performance
and (v) the assumptions underlying or relating to any statement
described in points (i), (ii), (iii) or (iv) above. Such
forward-looking statements are not meant to predict or guarantee
actual results, performance, events or circumstances and may not
be realized because they are based upon the Company’s current
projections, plans, objectives, beliefs, expectations, estimates
and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by
the forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the timing of planned expense
reductions, the Company’s inability to obtain adequate financing
to fund the Company’s operations and necessary to develop or
enhance our technology, the significant length of time and
resources associated with the development of the Company’s
products, the Company’s failure to achieve broad market
acceptance of the Company’s products, the failure of our sales
and marketing organization or partners to market our products
effectively, adverse results in future clinical studies of the
Company’s medical device products, the failure to obtain or
maintain patent protection for the Company’s technology, failure
to obtain or maintain regulatory approval to market the
Company’s medical devices, lack of product diversification,
existing or increased competition, and the Company’s failure to
implement the Company’s business plans or strategies. These and
other factors are identified and described in more detail in the
Company’s filings with the Securities and Exchange Commission,
including, but not limited to, its latest Annual Report on Form
10-K and subsequent Quarterly Reports on Form 10-Q. The Company
does not undertake to update these forward-looking statements.

On May 23, 2017, the Company issued a press release announcing
the events described above. A copy of the Companys press release
is attached hereto as Exhibit 99.1.

The information in this Item 7.01, including the exhibit attached
hereto, is furnished to Item 7.01 and shall not be deemed filed
for any other purpose, including for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section. The information in
this Item 7.01 shall not be deemed incorporated by reference into
any filing under the Securities Act of 1933 or the Exchange Act
of 1934 regardless of any general incorporation language in such
filing unless specifically provided otherwise.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Recent Trading Information

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) closed its last trading session down -0.14 at 1.29 with 1,089,876 shares trading hands.